Drug intelligence / Profile preview

pregabalin + duloxetine

Development stage: Unknown
Lead developer: Ardent Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

Pregabalin + duloxetine is a fixed-dose combination medication used primarily for treating neuropathic pain. It combines pregabalin, an anticonvulsant that binds to the α2δ subunit of voltage-dependent calcium channels, with duloxetine, a selective serotonin reuptake inhibitor (SSRI). This combination leverages complementary mechanisms of action to provide enhanced pain relief, particularly for patients with inadequate response to monotherapy.

Brand names: Pregaclas DPregamic-DUpnuron-DNervshine DPregacore-DTrigatrip DPrabin-DAppre DRejudeep DCymenka PG
Other names: Duloxetine/pregabalin

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on pregabalin + duloxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pregabalin + duloxetine.

Explore the full profile